Effect of SAMe-TT 2 R 2 score and genetic polymorphism on the quality of anticoagulation control in Qatari patients treated with warfarin

AbstractThere is no strong evidence on pharmacogenetics role on the quality of INR control after the initiation phase and on the maintenance of stable INR on the long term as measured by the time in therapeutic range (TTR). The benefit of a score such as SAMe-TT2R2 is that it can preemptively guide clinicians on whether to start the patient on warfarin or direct oral anticoagulant. To determine the association between genetic variants inCYP2C9, VKORC1, andCYP4F2 and TTR. To validate SAMe-TT2R2 score predictive ability on the quality of anticoagulation in Qatari patients. This is an observational nested case –control study that was conducted on a cohort of Qatari patients treated with warfarin with previously identified genotype for theCYP2C9, VKORC1, andCYP2F4. The sample size of this cohort was 148 patients. Mean TTR was 62.7  ± 21%. TTR was not significantly different among carriers of theCYP2C9*2&*3, VKORC1( –1639G>A) orCYP4F2*3 compared to their non-carriers alleles. None of the factors in the SAMe-TT2R2 score had a significant effect on the TTR except for the female gender where TTR was significantly lower in females (n  = 89) compared to males (n = 59) (59.6 ± 21% vs. 67.2 ± 20%, p = 0.03). Furthermore, patients with SAMe-TT2R2 score of zero had significantly better TTR compared to those with higher scores (76.5  ± 17% vs. 61.8 ± 21%, p = 0.04). Logistic regression analysis showed that high SAMe-TT2R2 score was the onl...
Source: Journal of Thrombosis and Thrombolysis - Category: Hematology Source Type: research